

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

<b>Name of entity</b>	<b>Pro Medicus Limited</b>
<b>ABN</b>	<b>25 006 194 752</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Peter Terence KEMPEN
<b>Date of last notice</b>	21 February 2022

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Ordinary fully paid shares in Pro Medicus Limited held by Elaine Kempen Superannuation Fund of which the Director is a Trustee and Member
<b>Date of change</b>	7 March 2023 8 March 2023 9 March 2023 10 March 2023 13 March 2023
<b>No. of securities held prior to change</b>	679,082 ordinary shares consisting of: - <ul style="list-style-type: none"><li>• 200,000 ordinary shares held under Peter Terence KEMPEN</li><li>• 478,082 ordinary shares held under Elaine Kempen Superannuation Fund of which the Director is a Trustee and Member</li><li>• 1,000 ordinary shares held under EMK Investments Pty Ltd of which the Director is a Director and beneficial owner</li></ul>
<b>Class</b>	Ordinary shares

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Number acquired</b>	Nil
<b>Number disposed</b>	7 March 2023 – 10,000 8 March 2023 – 15,000 9 March 2023 – 11,389 10 March 2023 – 10,000 13 March 2023 – 3,611 <b>Total – 50,000</b>
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	7 March 2023 - \$61.5691 per share 8 March 2023 - \$62.1807 per share 9 March 2023 - \$62.7975 per share 10 March 202 - \$61.1922 per share 13 March 2023 - \$61.2443 per share
<b>No. of securities held after change</b>	629,082 ordinary shares consisting of: - <ul style="list-style-type: none"> <li>• 200,000 ordinary shares held under Peter Terence KEMPEN</li> <li>• 428,082 ordinary shares held under Elaine Kempen Superannuation Fund of which the Director is a Trustee and Member</li> <li>• 1,000 ordinary shares held under EMK Investments Pty Ltd of which the Director is a Director and beneficial owner</li> </ul>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On market sales of shares

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

For and on behalf of Pro Medicus Limited



Clayton Hatch  
Company Secretary  
14 March 2023

---

<sup>+</sup> See chapter 19 for defined terms.